EINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical
N.V. (Euronext: ONWD), the medical technology company creating innovative spinal
cord stimulation therapies to restore movement, function, and independence in
people with spinal cord injury (SCI), today announces that the Company will be
highlighted in a main stage keynote at HLTH Europe, a premier event for digital
health leaders. The conference takes place June 17-20 in Amsterdam, the
Netherlands.
CEO Dave Marver and trial participant Gert-Jan Oskam will address conference
attendees in a keynote on the main stage on June 19, 2024. The pair will discuss
how investigational ARC-BCI Therapy uses artificial intelligence to enable
thought-driven movement after paralysis, the future of therapies to treat SCI,
and Gert-Jan's experience as the first human to be implanted with a brain-
computer interface to restore walking.
More than 3500 leaders are expected to attend this year's inaugural HLTH Europe,
which began in the US, where it is one of the leading health innovation
conferences in the country.
To learn more about ONWARD Medical's commitment to partnering with the SCI
Community to develop innovative solutions for restoring movement, function, and
independence after spinal cord injury, please visit ONWD.com
(https://www.onwd.com/).
*All ONWARD(®) Medical devices and therapies, including but not limited to ARC-
IM(®), ARC-EX(®), ARC-BCI((TM)), and ARC Therapy((TM)), alone or in combination with a
brain-computer interface (BCI), are investigational and not available for
commercial use.
About ONWARD Medical
ONWARD(®) Medical is a medical technology company creating therapies to restore
movement, function, and independence in people with spinal cord injury (SCI) and
movement disabilities. Building on more than a decade of scientific discovery,
preclinical, and clinical research conducted at leading hospitals,
rehabilitation clinics, and neuroscience laboratories, the Company has developed
ARC Therapy(TM), which has been awarded ten Breakthrough Device Designations from
the US Food and Drug Administration (FDA).
ONWARD ARC Therapy is targeted, programmed spinal cord stimulation designed to
be delivered by the Company's external ARC-EX(®) or implantable ARC-IM(®)
platforms. ARC Therapy can also be delivered by the Company's ARC-BCI(TM) platform,
which pairs the ARC-IM System with brain-computer interface (BCI) technology to
restore movement after SCI with thought-driven control.
Use of non-invasive ARC-EX Therapy significantly improved upper limb function
after SCI in the global pivotal Up-LIFT trial, with results published by Nature
Medicine in May 2024. The Company has submitted its regulatory application to
the FDA for clearance of the ARC-EX System in the US and is preparing for
regulatory submission in Europe. In parallel, the Company is conducting clinical
studies with its ARC-IM Therapy, which demonstrated positive interim clinical
outcomes for improved blood pressure regulation following SCI. Other ongoing
clinical studies focus on using ARC-IM Therapy to address mobility after SCI and
gait challenges in Parkinson's disease as well as using the ARC-BCI platform to
restore thought-driven movement of both upper and lower limbs after SCI.
Headquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and
Engineering Center in Lausanne, Switzerland and a US office in Boston,
Massachusetts. The Company is listed on Euronext Brussels and Amsterdam (ticker:
ONWD).
For more information, visit ONWD.com, and connect with us on LinkedIn and
YouTube.
For Media Inquiries:
Aditi Roy, VP Communications
media@onwd.com (mailto:media@onwd.com)
For Investor Inquiries:
Amori Fraser, Finance Director
investors@onwd.com (mailto:investors@onwd.com)
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-
looking, which reflect the Company's or, as appropriate, the Company directors'
current expectations and projections about future events. By their nature,
forward-looking statements involve several risks, uncertainties, and assumptions
that could cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These risks,
uncertainties, and assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition, and technology,
can cause actual events, performance, or results to differ significantly from
any anticipated development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. As a
result, the Company expressly disclaims any obligation or undertaking to release
any update or revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events, conditions,
assumptions, or circumstances on which these forward-looking statements are
based. Neither the Company nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are free from
errors nor does either accept any responsibility for the future accuracy of the
forward-looking statements contained in this press release or the actual
occurrence of the forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the date of this press
release. All ONWARD Medical devices and therapies referenced here, including but
not limited to ARC-IM(®), ARC-EX(®), ARC-BCI(TM) and ARC Therapy(TM), are
investigational and not available for commercial use.
Â